Go To Main content
Title:Cell Therapy Center of Tri-Service General Hospital (TSGH) and AccuHealth Bio-Tech Holding Group sign MOU on medical R&D collaboration.
Published day:2020/5/5

Content



Tri-Service General Hospital (TSGH) has instituted the Cell Therapy Center in 2018 and opened a new chapter in terms of offering brand new model of cancer treatments for patients under its care. TSGH has further inked memorandum of understanding (MOU) on medical R&D with AccuHealth Bio-Tech Holding Group on May 5th, 2020. During the MOU signing ceremony TSGH and AccuHealth Bio-Tech Holding Group jointly announced that both parties will launch extensive collaborative projects in clinical care and services and bring about a new milestone for cell therapy technologies and applications. The collaborative partnership between TSGH and AccuHealth Bio-Tech Holding Group will initially focus on integrating medical industry chain, clinical trials, as well as planning and consultation services for cell therapy, making Cell Therapy Center of TSGH a one-stop-shop capable of offering comprehensive solutions for patients seeking cell therapy.

Dr. Chien-Sung, TSAI, Superintendent of TSGH stated that Cell Therapy Center of TSGH would offer patients the fourth largest model and choice for cancer treatments, in addition to surgeries, radiotherapies, and chemotherapies. In complying with all guidelines and regulations stipulated in the “Administrative Measures for the Implementation or Use of Specific Medical Technology and Inspection, Diagnostic or Medical Devices” promulgated by Ministry of Health and Welfare (MOHW), TSGH medical staffs aim to provide more precise and effective healthcare solutions for cancer patients under their care.

Collaboration between TSGH and AccuHealth Bio-Tech Holding Group on cell therapy and precision medicine carries significant meaning for both parties. AccuHealth Bio-Tech Holding Group is not only a biotech company having industrial-and-academic cooperative relationship with National Defense Medical Center (NDMC), it is also a GTP compliant medical lab certified and promulgated by Taiwan Ministry of Health and Welfare (MOHW). To deepen their industrial-and-academic collaboration and strengthen clinical applications, both parties in the near future will kick-start collaborative projects on cancer treatment, regenerative medicine, infectious diseases, neuralgia (nerve pain), and precision medicine, for example by pooling together and sharing clinical and lab resources, jointly conducting cell therapy clinical trials, offering exchange opportunities for hospital clinicians and lab technicians, and providing consultation services regarding cell therapy planning and implementing. Both parties hope to jointly explore and expand innovative and diverse healthcare models and treatment options for patients seeking care.


CellTherapyCentersignMOU


CellTherapyCentersignMOU


CellTherapyCentersignMOU


CellTherapyCentersignMOU




text-to-speech
Views:269
UpdateDate:2020-09-25T14:47:54
Web Priority AA Accessibility Approval_image
Republic of China (Taiwan) Govemment Entry Point_image